Gentian: What the Clinical Evidence Shows

Table of Contents

1. The Short Answer
2. How to Weigh the Different Kinds of Study
3. The Old Secretion Studies
4. The 1981 Controlled Study
5. The 205-Patient Open Study
6. The Blood-Vessel Reflex Studies
7. Combination Medicines Containing Gentian
8. The STW 5 Confusion: A Bitter Combination Without Gentian
9. What the Reviews Claim, and What They Contain
10. What Is Known About Safety in People
11. What a Fair Trial Would Measure
12. The Bottom Line
13. Key Research Papers
14. Connections

The Short Answer

• No randomised, placebo-controlled trial of gentian root alone for appetite or indigestion was found in our PubMed search or listed by the EMA.
• One open study of 205 patients taking gentian extract capsules reported improvement, but had no comparison group.
• A few small physiology studies in healthy people show that gentian increases saliva and gastric secretion and triggers a blood-vessel reflex when tasted.
• Combination products containing gentian have a little observational data; the best-known trialled herbal combination for indigestion does not contain gentian at all.
• Everything else — obesity, diabetes, liver, skin, cancer — is from cell and animal research.

How to Weigh the Different Kinds of Study

Not all studies answer the same question. In plain terms:

• Cell and tissue studies show whether a substance can do something to cells in a dish, usually at concentrations that may never be reached in the body.
• Animal studies show whether an effect appears in a living body, but often at high doses, in specially induced disease models, and in species that differ from us.
• Physiology studies in healthy people show whether the body responds (more saliva, a change in blood pressure). They do not show that symptoms improve.
• Open or observational studies follow people who take a remedy. Without a comparison group, they cannot separate the remedy's effect from natural recovery, the placebo response or regression to the mean (symptoms tend to be measured when they are at their worst and drift back toward normal).
• Randomised, placebo-controlled trials compare similar groups who receive the real product or a dummy, ideally without anyone knowing which. They are the standard for showing that a treatment relieves symptoms.

For gentian root, the evidence sits almost entirely in the first four categories.

The Old Secretion Studies

The EMA assessment report summarises a handful of human studies from the 20th century (EMA assessment report):

• 1938: refined gentian extracts given to 5 healthy volunteers were followed by X-ray images showing a thickened stomach lining and more mucus.
• 1966 and 1967: two studies found that an oral ethanolic gentian extract stimulated saliva and gastric juice, and reported an effect on bile flow.
• 1986: a dilute gentian tincture (labelled D1) lowered a salivary immune marker, secretory IgA, which is raised in people with inflammatory digestive disease.
• 1988: a multi-herb bitter concentrate, not described in detail, was reported to improve gastric acid production in healthy volunteers.

The report notes that "exact descriptions of the extract administered are missing." These studies support the idea that bitters stimulate digestive secretions. They were not designed to show symptom relief, and they cannot be repeated exactly because the preparations are not known.

The 1981 Controlled Study

The closest thing to a controlled trial in the EMA report is a 1981 study by Borgia and colleagues (EMA assessment report). It had two parts:

• In 24 healthy volunteers, six treatments were compared in a crossover design. A 2% gentian tincture, like the full herbal product and a citric-acid control, increased salivary secretion over 30 minutes; placebo and placebo with alcohol did not. There were no differences at later times.
• In 80 patients with mild digestive complaints, randomised into four groups of 20, the full product (rhubarb, cascara, boldo and gentian) did better than placebo and better than either pair of its ingredients. Gentian was tested only together with rhubarb, never on its own.

The EMA left this study out of its table of clinical studies for that reason: in the patient part, gentian was always combined with another herb.

The 205-Patient Open Study

The only clinical study of gentian root alone listed by the EMA is an open, non-interventional study published by Wegner in 1997 (EMA assessment report):

• Who: 205 patients, average age 53, 65% women, with mixed digestive symptoms — heartburn, vomiting, stomach ache, nausea, loss of appetite, constipation and wind.
• What: capsules of 120 mg dry gentian root extract, 2 to 3 times a day; on average 4.8 capsules daily, equivalent to about 2.9 g of root, for 15 days.
• Results: symptoms improved in most cases within 5 days; by the end, the average improvement was 68%. Doctors rated the effect excellent in 31%, good in 55%, moderate in 9% and inadequate in 5%.
• Side effects: 2.4% reported an adverse event.

Without a placebo group, none of this can be credited to gentian. Without a comparison group, improvement over two weeks cannot be separated from natural recovery or the placebo response. The EMA's own wording is that the study "only supports the plausibility" of using gentian extract in a solid form. It is cited here through the EMA report.

The Blood-Vessel Reflex Studies

A modern line of human research comes from a group that tested gentian and wormwood in healthy adults. Tasted in flavoured water, both herbs raised the tone of the resistance blood vessels within about 5 minutes in a dose-dependent reflex; in capsules, they did not alter the stomach-phase response (McMullen 2015). The authors propose that this reflex helps maintain blood flow to the gut after a meal.

This is good physiology, and it supports the long-held view that bitters act partly through taste. It is not a clinical trial: participants were healthy, and the outcome was a cardiovascular measurement, not appetite or indigestion. Its details are explained in Bitter Taste Receptors and Digestion.

Combination Medicines Containing Gentian

Gentian is often sold as one ingredient among several. The EMA notes that gentian root "is often used in combination with other bitters or preparations from other herbal substances." Combinations are hard to assess, because any effect could come from another ingredient.

A 2018 systematic review of anthroposophic treatments for acute gastroenteritis in children screened 3,086 articles and found observational studies for two anthroposophic medicines, one of them a gentian-containing combination. The review concluded that studies of these approaches "are deficient" and that clinical evaluation is still needed (Schwermer 2018). No randomised trial of such a combination was identified.

The STW 5 Confusion: A Bitter Combination Without Gentian

The best-studied herbal treatment for functional dyspepsia (chronic indigestion with no structural cause) is a liquid combination coded STW 5 in trials. Because it is a bitter herbal digestive, it is easy to assume it contains gentian. It does not. The original product's published ingredient list is nine herbs: bitter candytuft, angelica root, chamomile, caraway, milk thistle, lemon balm, peppermint, greater celandine and liquorice (healthdirect ingredient listing). Its bitter component is bitter candytuft (Iberis amara). A newer six-herb version, coded STW 5-II, has its own trials (Andresen 2024).

The trials themselves are informative about herbal bitters in general, so here is what they found:

• A 2004 meta-analysis pooled three placebo-controlled trials of STW 5 (138 on the product, 135 on placebo) and found it more effective than placebo for the most bothersome digestive symptom; side effects were similar to placebo (Melzer 2004).
• A 2009 trial in 103 patients with functional dyspepsia found that STW 5 did not speed up stomach emptying, so its effect on symptoms is not explained by faster emptying; symptom improvement was borderline overall but the proportion of responders was higher than with placebo (Braden 2009).
• In healthy men, a single dose relaxed the upper stomach and increased contractions in its lower part without changing how fast solids left the stomach (Pilichiewicz 2007).
• A 2024 analysis of individual patient data from randomised trials of the six-herb STW 5-II reported improvement in fullness, early satiety and upper abdominal pain at 4 and 8 weeks, with no difference in safety signals from placebo (Andresen 2024).
• A 2025 trial in 32 patients found STW 5-II reduced bloating in a gas-challenge test (Aguilar 2025).

None of these results is evidence for gentian. They show that a bitter-containing herbal combination can be tested rigorously — which makes the absence of such trials for gentian root more noticeable, not less.

What the Reviews Claim, and What They Contain

Reading gentian reviews alongside their sources is instructive:

• A 2023 systematic review describes "in vitro/vivo investigations and human interventional trials" showing promising activity against oxidative stress, infection, inflammation, obesity and atherosclerosis, and presents gentian as a source of compounds that "can prevent and treat several human illnesses" (Ponticelli 2023). The abstract does not identify any randomised trial of gentian root for a disease outcome, and we found none in PubMed.
• Reviews from one research group discuss gentian for obesity, diabetes and vascular disease and conclude that "Gentiana-based therapeutics represent potentially useful drugs" (Joksić 2019; Joksic 2021). The studies they draw on are mainly in cells and animals.
• A 2024 review of gentiopicroside's mechanisms deliberately restricted itself to cell and animal studies (Liu 2024).
• The 2025 review of gentiopicroside is the most candid, listing "methodological gaps, preclinical inconsistencies and weak clinical evidence (no large-scale randomized controlled trials [RCTs])" (Kui 2025).

The underlying preclinical studies — loganic acid in fat cells and mice (Park 2018), gentiopicroside in fatty-liver mice (Yong 2024), amarogentin in diabetic rats (Niu 2016), gentian extract in rat intestine (Kitić 2024) — are real findings. They are reasons to run human trials, not substitutes for them.

What Is Known About Safety in People

Human safety data are as thin as efficacy data. The EU monograph lists no known undesirable effects, no reported interactions and no reported overdose (EU herbal monograph). The evidence behind that is long traditional use, the open study's 2.4% adverse-event rate, and a single report of raised blood pressure in a person with known hypertension in more than 30 years of German pharmacovigilance data.

What has not been done is equally important: no tests of reproductive toxicity, genotoxicity or cancer risk on gentian root preparations, and some isolated xanthones from the plant were positive in a bacterial mutation test. On that basis the EMA declined to add gentian root to its official EU list of traditional herbal substances, and its monograph states that use in pregnancy and breastfeeding "is not recommended" and that use under 18 has not been established. The main documented danger in people is poisoning by the look-alike plant Veratrum album; see Veratrum Mix-Ups and Poisoning.

What a Fair Trial Would Measure

The questions that remain open are answerable. A trial able to settle gentian's main traditional claim would involve, at minimum:

• a defined, standardised preparation, with its gentiopicroside and amarogentin content reported;
• a clearly defined group, for example adults meeting standard criteria for functional dyspepsia, or people with documented poor appetite;
• a placebo that matches the bitterness, which is genuinely difficult, since an unbitter placebo would unblind participants immediately;
• a comparison of tasted and encapsulated forms, given the physiology results;
• validated symptom scores over several weeks, and safety monitoring.

The bitterness problem may be one reason such trials are rare: it is hard to hide which group is getting the real thing. That is an explanation for the gap, not a reason to treat the gap as evidence.

The Bottom Line

Gentian root's traditional use for appetite and indigestion is plausible, consistent with what is known about bitter taste, and accepted by European regulators as traditional use. The human evidence for it consists of small old secretion studies, one controlled study in which gentian was always combined with another herb, one uncontrolled 205-patient study, and physiology experiments in healthy volunteers. No randomised, placebo-controlled trial of gentian root alone has been published. The well-known positive trials of bitter herbal combinations for indigestion tested products that do not contain gentian.

Key Research Papers

1. McMullen MK, Whitehouse JM, Towell A. Bitters: Time for a New Paradigm. Evidence-based complementary and alternative medicine : eCAM. 2015;2015:670504. PubMed PMID: 26074998
2. Schwermer M, Längler A, Fetz K, et al. [Management of Acute Gastroenteritis in Children: A Systematic Review of Anthroposophic Therapies]. Complementary medicine research. 2018;25(5):321-330. PubMed PMID: 30041164
3. Melzer J, Rösch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Alimentary pharmacology & therapeutics. 2004;20(11-12):1279-87. PubMed PMID: 15606389
4. Braden B, Caspary W, Börner N, et al. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterology and motility. 2009;21(6):632-8, e25. PubMed PMID: 19220753
5. Pilichiewicz AN, Horowitz M, Russo A, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. The American journal of gastroenterology. 2007;102(6):1276-83. PubMed PMID: 17378904
6. Andresen V, Shah A, Fink C, et al. Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis. Digestion. 2024;105(3):166-174. PubMed PMID: 38246134
7. Aguilar A, Alcala-Gonzalez L, Barber C, et al. Effect of STW 5-II (Iberogast-N) on Tolerance to Gastric Gas in Patients With Functional Dyspepsia. The IBO-2 Study. Neurogastroenterology and motility. 2025;37(11):e70123. PubMed PMID: 40684457
8. Ponticelli M, Lela L, Moles M, et al. The healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic review. Phytochemistry. 2023;206:113518. PubMed PMID: 36423749
9. Joksić G, Tričković JF, Joksić I. Potential of Gentiana lutea for the Treatment of Obesity-associated Diseases. Current pharmaceutical design. 2019;25(18):2071-2076. PubMed PMID: 31538881
10. Joksic G, Radak D, Sudar-Milovanovic E, et al. Effects of Gentiana lutea Root on Vascular Diseases. Current vascular pharmacology. 2021;19(4):359-369. PubMed PMID: 32469702
11. Liu B, Pang F, Bi H, et al. Regulatory mechanisms of Gentiopicroside on human diseases: a brief review. Naunyn-Schmiedeberg's archives of pharmacology. 2024;397(2):725-750. PubMed PMID: 37632552
12. Kui L, Wang G, Huang J, et al. Therapeutic efficacy and mechanisms of gentiopicroside in various diseases. Frontiers in pharmacology. 2025;16:1634722. PubMed PMID: 41378205
13. Park E, Kim J, Yeo S, et al. Antiadipogenic Effects of Loganic Acid in 3T3-L1 Preadipocytes and Ovariectomized Mice. Molecules (Basel, Switzerland). 2018;23(7). PubMed PMID: 29987205
14. Yong Q, Huang C, Chen B, et al. Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024;177:116952. PubMed PMID: 38917754
15. Niu HS, Chao PC, Ku PM, et al. Amarogentin ameliorates diabetic disorders in animal models. Naunyn-Schmiedeberg's archives of pharmacology. 2016;389(11):1215-1223. PubMed PMID: 27485449
16. Kitić N, Živković J, Šavikin K, et al. Spasmolytic Activity of Gentiana lutea L. Root Extracts on the Rat Ileum: Underlying Mechanisms of Action. Plants (Basel, Switzerland). 2024;13(3). PubMed PMID: 38337986

PubMed Topic Searches

1. PubMed: Gentiana lutea clinical trials
2. PubMed: Gentian root and dyspepsia
3. PubMed: Bitter herbs in functional dyspepsia trials
4. PubMed: Gentiopicroside clinical studies

Regulatory Sources

1. EMA assessment report on Gentiana lutea L., radix, Revision 1 (sections 4 and 5)
2. European Union herbal monograph on Gentiana lutea L., radix
3. healthdirect (Australia): ingredient listing of the nine-herb STW 5 combination

Connections

• All Herbs
• Digestive and Gut Herbs — the category this herb belongs to
• Gentian (Gentiana lutea) — the main research page
• Gentian: Benefits — the evidence hub and ledger
• Bitter Taste Receptors and Digestion — how a bitter is supposed to work
• Gentian in Bitters and Aperitifs — the root in food and drink
• Veratrum Mix-Ups and Poisoning — the dangerous look-alike
• Functional Dyspepsia — the condition, and its treatments with evidence
• Gastroparesis — slow stomach emptying
• Peppermint: IBS and Digestive — another digestive herb covered on this site
• Chamomile — one of the STW 5 herbs
• Milk Thistle — another STW 5 herb
• Chiretta: Benefits — a related bitter with the same evidence gap
• Blessed Thistle: Bitter Digestive and Appetite — another traditional bitter under scrutiny

Back to Table of Contents